These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 21403460)

  • 21. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.
    Chen YM; Perng RP; Lee YC; Shih JF; Lee CS; Tsai CM; Whang-Peng J
    Ann Oncol; 2002 Jan; 13(1):108-15. PubMed ID: 11863090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.
    Kanai K; Kikuchi E; Ohigashi T; Miyajima A; Nakagawa K; Nakashima J; Oya M
    Int J Clin Oncol; 2008 Dec; 13(6):510-4. PubMed ID: 19093178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
    Bellmunt J; von der Maase H; Mead GM; Skoneczna I; De Santis M; Daugaard G; Boehle A; Chevreau C; Paz-Ares L; Laufman LR; Winquist E; Raghavan D; Marreaud S; Collette S; Sylvester R; de Wit R
    J Clin Oncol; 2012 Apr; 30(10):1107-13. PubMed ID: 22370319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
    Hainsworth JD; Meluch AA; Litchy S; Schnell FM; Bearden JD; Yost K; Greco FA
    Cancer; 2005 Jun; 103(11):2298-303. PubMed ID: 15856431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
    Hainsworth JD; Burris HA; Erland JB; Morrissey LH; Meluch AA; Kalman LA; Hon JK; Scullin DC; Smith SW; Greco FA
    Cancer; 1999 Mar; 85(6):1269-76. PubMed ID: 10189131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy.
    Nogué-Aliguer M; Carles J; Arrivi A; Juan O; Alonso L; Font A; Mellado B; Garrido P; Sáenz A;
    Cancer; 2003 May; 97(9):2180-6. PubMed ID: 12712469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II Study of Second-line Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin for Advanced Urothelial Carcinoma.
    Ogawa M; Yamamoto S; Inoue T; Numao N; Yuasa T; Masuda H; Fukui I; Yonese J
    Anticancer Res; 2020 Mar; 40(3):1613-1618. PubMed ID: 32132064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel.
    Edelman MJ; Gandara DR; Lau DH; Lara P; Lauder IJ; Tracy D
    Cancer; 2001 Jul; 92(1):146-52. PubMed ID: 11443620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.
    Hussain M; Vaishampayan U; Du W; Redman B; Smith DC
    J Clin Oncol; 2001 May; 19(9):2527-33. PubMed ID: 11331332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study.
    Siefker-Radtke AO; Campbell MT; Munsell MF; Harris DR; Carolla RL; Pagliaro LC
    Urology; 2016 Mar; 89():83-9. PubMed ID: 26723185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma.
    An X; Xue C; Chen M; Ni M; Ma H; Tian L; Huang R; Li X; Ye Y; Qin T; Dong P; Li Z; Peng J; Yao K; Zhou F; Liu Z; Shi Y
    BJU Int; 2024 Jul; 134(1):63-71. PubMed ID: 38009394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Gemcitabine and cisplatin (GC) or gemcitabine and carboplatin (GCarbo) in patients with metastatic urothelial cancer].
    Sumiyoshi T; Matsumoto K; Utsunomiya N; Segawa T; Muguruma K; Kawakita M
    Hinyokika Kiyo; 2013 Jan; 59(1):1-6. PubMed ID: 23412116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM).
    Holmsten K; Jensen NV; Mouritsen LS; Jonsson E; Mellnert C; Agerbæk M; Nilsson C; Moe M; Carus A; Öfverholm E; Lahdenperä O; Brandberg Y; Johansson H; Hellström M; Maase HV; Pappot H; Ullén A
    Eur J Cancer; 2020 Mar; 127():173-182. PubMed ID: 31648851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
    Micha JP; Goldstein BH; Rettenmaier MA; Mattison J; Graham C; Birk CL; Brown JV
    Gynecol Oncol; 2004 Sep; 94(3):719-24. PubMed ID: 15350364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study.
    Papadimitriou CA; Fountzilas G; Aravantinos G; Kalofonos C; Moulopoulos LA; Briassoulis E; Gika D; Dimopoulos MA;
    Gynecol Oncol; 2004 Jan; 92(1):152-9. PubMed ID: 14751151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer.
    Friedland DM; Dakhil S; Hollen C; Gregurich MA; Asmar L
    Cancer Invest; 2004; 22(3):374-82. PubMed ID: 15493358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).
    du Bois A; Belau A; Wagner U; Pfisterer J; Schmalfeldt B; Richter B; Staehle A; Jackisch C; Lueck HJ; Schroeder W; Burges A; Olbricht S; Elser G;
    Gynecol Oncol; 2005 Feb; 96(2):444-51. PubMed ID: 15661234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function.
    Demery ME; Thézenas S; Pouessel D; Culine S
    Anticancer Drugs; 2012 Feb; 23(2):143-8. PubMed ID: 21934599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
    Halim A; Abotouk N
    Asia Pac J Clin Oncol; 2013 Mar; 9(1):60-5. PubMed ID: 22897883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.